Home » Interviews » Cambridge Cognition CEO Matthew Stork Excited over potential for growth (Interview)
Cambridge Cognition

Cambridge Cognition CEO Matthew Stork Excited over potential for growth (Interview)

Cambridge Cognition plc (LON:COG) CEO Matthew Stork joins DirectorsTalk to chat about preliminary results for 2019. Matthew talks us through the highlights, explains why Q1 2020 order intake has been so positive, the impact of COVID-19 and shares his thoughts on the coming months and the future for the company.

Cambridge Cognition is a neuroscience technology company developing digital health products to better understand, detect and treat conditions affecting brain health. The company’s software products assess cognitive health in patients worldwide to improve clinical trial outcomes, identify and stratify patients early and improve global efficiency in pharmaceutical and healthcare industries.

Join us on our new LinkedIn page

Follow us on LinkedIn